Collaboration will leverage new method discovered by Vibalogics.
Advaxis and Vibalogics are co-developing a room temperature stable processing technology for live vaccines originally engineered by Advaxis. Vibalogics has reportedly found a new method that allows for a room temperature storage-stable form of Advaxis’ live Listeria vaccines with high recovery.
“This process, which we are currently developing for our Listeria immunotherapeutics, shows promise in its use with other living microorganisms,” comments Advaxis’ chairman/CEO Thomas A. Moore. “Although it is intended for use with Listeria, other companies and academic institutions that use living microorganisms may benefit from this process.
“This initiative does not require significant development funds from Advaxis, vastly increases the commercial properties of our products, and can increase our short- and long-term shareholder value.”
Most live vaccines are stored via a freeze-drying process called lyophilization. This drying method may not be suitable for all products as it frequently kills most of the microorganism depending upon the organism type and related recovery and stability issues, the companies explain.
Advaxis says that its live, attenuated Listeria monocytogenes vaccines, which deliver engineered tumor antigens, stimulate multiple, simultaneous immunological mechanisms to fight cancer. The company has nine distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with organizations like City of Hope, Roswell Park Cancer Institute, NCI, University of Pittsburgh, and Cancer Research UK.
Vibalogics has a site for GMP-compliant manufacturing, formulating, filling, and lyophilization of drugs based on recombinant or wild-type viruses and bacteria.